Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chuikyo Healthcare Rep Wants Off-Year Re-Pricing Threshold Set at 2 Times-Plus Average Price Gap, Payers Want Further Estimates for Larger Product Coverage
A key drug pricing panel on December 11 held a hearing with pharma trade groups and discussed the planned off-year re-pricing next April, but healthcare providers and payers remained deeply divided over the scope of products that should be covered…
To read the full story
Related Article
- MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
- Special Mitigation Margin for COVID-19 Up for Debate towards FY2022 Drug Price Revision: MHLW Bureau Chief
January 15, 2021
- Chuikyo OKs Revised NHI Pricing Rules for FY2021 Drug Re-Pricing
January 14, 2021
- Chuikyo OKs Outline of FY2021 Off-Year Re-Pricing; Only Market Price-Linked Rules to Be Applied
December 21, 2020
- Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
- Govt Settles on Discrepancy Rate Threshold of “Above 5%” for Off-Year Drug Re-Pricing, 430 Billion Yen Reduction, 60% Coverage for Innovative Meds
December 17, 2020
- Japan Govt Eyes 4-6% Price Discrepancy Threshold for Off-Year Drug Re-Pricing
December 16, 2020
- Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too
December 15, 2020
- Chuikyo Healthcare Reps Urge Minimal Scope for Off-Year Re-Pricing, Payers Grumble over Generic-Heavy Coverage
December 10, 2020
- MHLW Estimates: Off-Year Re-Pricing with Average Price Gap Threshold Likely to Hit 8,700 Products, Save 360 Billion Yen
December 9, 2020
REGULATORY
- MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
- Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
- Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
- Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
July 9, 2026
- JPA’s Watanabe Joins Chuikyo as Healthcare Provider Rep
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…